Table 2.

Postoperative complications and medications

Variable		Total population(n = 262)		Survivors(n = 156)	Non-survivors(n = 106)		p value
Post-TAVR Complications
Permanent pacemaker implantation, n (%)		21 (8.0%)		9 (5.8%)	12 (11.3%)		0.164
CVD development, n (%)		8 (3.1%)		3 (1.9%)	5 (4.7%)		0.355
Cardiac tamponade, n (%)		7 (2.7%)		0 (0.0%)	7 (6.6%)		0.004
In-hospital arrhythmia, n (%)		45 (17.2%)		21 (13.5%)	24 (22.6%)		0.077
Acute kidney injury, n (%)		14 (5.3%)		5 (3.2%)	9 (8.5%)		0.112
Major bleeding, n (%)		14 (5.3%)		1 (0.6%)	13 (12.3%)		< 0.001
Myocardial infarction, n (%)		3 (1.1%)		2 (1.3%)	1 (0.9%)		1.000
Coronary obstruction, n (%)		1 (0.4%)		0 (0.0%)	1 (0.9%)		0.846
LBBB development, n (%)		88 (33.6%)		48 (30.8%)	40 (37.7%)		0.250
After TAVR Medications
ASA or P2Y12 Inhibitors, n (%)		238 (90.8%)		150 (96.2%)	88 (83.0%)		0.489
Warfarin, n (%)		12 (4.6%)		9 (5.8%)	3 (2.8%)		0.389
Oral anticoagulants, n (%)		37 (14.1%)		22 (14.1%)	15 (14.2%)		0.748

ASA Acetylsalicylic acid, CVD Cerebrovascular disease, TAVR Transcatheter aortic valve replacement